Patricia D Walshaw1, Laszlo Gyulai2,3, Michael Bauer4, Mark S Bauer5, Brian Calimlim1,6, Catherine A Sugar1,6, Peter C Whybrow1. 1. Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, California, USA. 2. Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 3. Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA. 4. Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 5. Department of Psychiatry, VA Boston Healthcare System, Harvard Medical School & the Center for Healthcare Organization and Implementation Research, Boston, Massachusetts, USA. 6. Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles (UCLA), Los Angeles, California, USA.
Abstract
OBJECTIVES: This report describes the first comparative double-blind, placebo-controlled trial of levothyroxine (L-T4 ) and triiodothyronine (T3 ) as adjunctive treatments in rapid cycling bipolar disorder. METHODS:Thirty-two treatment-resistant, rapid cycling patients who had failed a trial of lithium were randomized into three treatment arms: L-T4 , T3 , or placebo. They were followed for ≥4 months with weekly clinical and endocrine assessments. RESULTS: There were no statistically significant differences between the groups in age, gender, duration of illness, or thyroid status. Markov chain analyses were employed to assess treatment effects on cycling patterns among mood states (euthymia, depression, mania, and mixed). Within groups, post-treatment the L-T4 group spent significantly less time depressed or in a mixed state and greater time euthymic. The T3 and placebo groups did not differ significantly pre- and post-treatment in any mood state, although the pattern of effects was the same for the T3 group as for the L-T4 group. Between groups, the L-T4 group had a significantly greater increase in time euthymic and decrease in time in the mixed state than the placebo group. Other group differences were not significant, although they were in the expected direction. CONCLUSIONS: The findings in this first double-blind study directly comparing the effects of L-T4 and T3 therapy against placebo provide evidence for the benefit of adjunctive L-T4 in alleviating resistant depression, reducing time in mixed states and increasing time euthymic. Adjunctive T3 did not show statistically significant evidence of benefit over placebo in reducing the time spent in disturbed mood states.
RCT Entities:
OBJECTIVES: This report describes the first comparative double-blind, placebo-controlled trial of levothyroxine (L-T4 ) and triiodothyronine (T3 ) as adjunctive treatments in rapid cycling bipolar disorder. METHODS: Thirty-two treatment-resistant, rapid cycling patients who had failed a trial of lithium were randomized into three treatment arms: L-T4 , T3 , or placebo. They were followed for ≥4 months with weekly clinical and endocrine assessments. RESULTS: There were no statistically significant differences between the groups in age, gender, duration of illness, or thyroid status. Markov chain analyses were employed to assess treatment effects on cycling patterns among mood states (euthymia, depression, mania, and mixed). Within groups, post-treatment the L-T4 group spent significantly less time depressed or in a mixed state and greater time euthymic. The T3 and placebo groups did not differ significantly pre- and post-treatment in any mood state, although the pattern of effects was the same for the T3 group as for the L-T4 group. Between groups, the L-T4 group had a significantly greater increase in time euthymic and decrease in time in the mixed state than the placebo group. Other group differences were not significant, although they were in the expected direction. CONCLUSIONS: The findings in this first double-blind study directly comparing the effects of L-T4 and T3 therapy against placebo provide evidence for the benefit of adjunctive L-T4 in alleviating resistant depression, reducing time in mixed states and increasing time euthymic. Adjunctive T3 did not show statistically significant evidence of benefit over placebo in reducing the time spent in disturbed mood states.
Authors: M Bauer; E D London; N Rasgon; S M Berman; M A Frye; L L Altshuler; M A Mandelkern; J Bramen; B Voytek; R Woods; J C Mazziotta; P C Whybrow Journal: Mol Psychiatry Date: 2005-05 Impact factor: 15.992
Authors: Michael Bauer; Anne Berghöfer; Tom Bschor; Andreas Baumgartner; Ursula Kiesslinger; Rainer Hellweg; Mazda Adli; Christopher Baethge; Bruno Müller-Oerlinghausen Journal: Neuropsychopharmacology Date: 2002-10 Impact factor: 7.853
Authors: Jennifer B Dwyer; Awais Aftab; Rajiv Radhakrishnan; Alik Widge; Carolyn I Rodriguez; Linda L Carpenter; Charles B Nemeroff; William M McDonald; Ned H Kalin Journal: Am J Psychiatry Date: 2020-05-27 Impact factor: 18.112
Authors: Aleksander Kuś; Alisa D Kjaergaard; Eirini Marouli; Fabiola Del Greco M; Rosalie B T M Sterenborg; Layal Chaker; Robin P Peeters; Tomasz Bednarczuk; Bjørn O Åsvold; Stephen Burgess; Panos Deloukas; Alexander Teumer; Christina Ellervik; Marco Medici Journal: Thyroid Date: 2021-05-26 Impact factor: 6.506
Authors: Maximilian Pilhatsch; Thomas J Stamm; Petra Stahl; Ute Lewitzka; Anne Berghöfer; Cathrin Sauer; Michael Gitlin; Mark A Frye; Peter C Whybrow; Michael Bauer Journal: Int J Bipolar Disord Date: 2019-10-04